Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05636696
Other study ID # 202100817
Secondary ID KWF-12794NL80201
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 21, 2022
Est. completion date March 21, 2024

Study information

Verified date July 2023
Source University Medical Center Groningen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic cancer-related fatigue (CCRF) is a disturbing condition that persists in up to 25% of cancer patients after completion of treatment. While mindfulness-based interventions are effective in relieving CCRF, these typically target the patient alone. Growing evidence suggests that including partners and targeting the dyadic context can increase and broaden the interventions' efficacy. The proposed study is a pilot trial testing the acceptability and potential efficacy of a mindfulness intervention directed at couples.


Description:

This is a 1-arm pilot trial. Recruitment will take place via a hospital, the Helen Dowling Institute and self-referral. The target is to include 34 couples (i.e. 68 participants). All participating cancer patients and their partners will be allocated to the couple mindfulness-based cognitive behavioral therapy, provided via internet (couple eMBCT), called 'COMPANION' (in Dutch: 'Samen Minder Moe') Assessments include three questionnaires (i.e. before starting the intervention (T0), after completing the intervention (T1), and 1 month after T1 (T2)). The assessments include also weekly diaries during a period of 17-22 weeks. A subsample of patients (n ≈ 5) and partners (n ≈ 5) as well as the therapists providing the couple eMBCT will participate in final focus groups. The primary objectives of COMPANION study 2 are to determine the acceptability of the couple intervention and the potential efficacy for patient fatigue. Secondary objectives are to examine the feasibility of trial procedures and the potential working mechanisms of the couple intervention.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 68
Est. completion date March 21, 2024
Est. primary completion date January 21, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Only couples are eligible for participation. In order to be eligible, the couple must meet each of the following criteria: 1. The patient has received a cancer diagnosis (all malignancies will be included); 2. The patient completed cancer treatment with either curative or palliative intent = 3 months earlier. Patients who currently receive hormone therapy are eligible; 3. The patient experiences severe levels of fatigue (score of = 35 on the Checklist Individual Strength, subscale fatigue severity (CIS-fatigue)); 4. The patient has been suffering from severe fatigue for = 3 months (as self-reported by the patient); 5. The patient was = 18 years old at disease onset; 6. The partner is = 18 years old; 7. Both couple members live together; 8. Both couple members have good command of the Dutch language (checked implicitly during registration); 9. Both couple members have adequate computer literacy and have access to an internet-connected computer, laptop or tablet (based on self-report); 10. Both couple members agree to participate in the research. Exclusion Criteria: The couple will be excluded in case: 1. The patient is currently following an evidence-based therapy for CCRF (i.e. Cognitive-Behavioral Therapy, mindfulness-based therapy, exercising/physiotherapy) as self-reported at the (telephone) screening; 2. The patient suffers from a condition that can explain his/her fatigue and is potentially treatable (e.g. anemia); 3. The therapist decides, based on information collected during the intake session, that the intervention is not suitable for the couple. Criteria that will be considered include, but are not limited to: - presence of severe psychiatric morbidity such as suicidal ideation and/or psychosis (as assessed by the therapist at the intake session). Mild depression is not an exclusion criterion. A score of = 20 on the Hospital Anxiety and Depression Scale (HADS) at T0 is considered indicative of depression. Therefore, if the patient or the partner scores = 20, the therapist will determine at the intake whether the participant has suicidal ideation or suffers from other severe psychiatric morbidity. A participant (and thus the couple) will be excluded if, according to the therapist, that is the case; - presence of substance abuse, except for smoking.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Samen Minder Moe (Dutch intervention name)
'Samen Minder Moe' is a mindfulness-based cognitive behavioral therapy for cancer-related fatigue directed at couples.

Locations

Country Name City State
Netherlands Helen Dowling Institute Bilthoven
Netherlands University Medical Center Groningen Groningen

Sponsors (2)

Lead Sponsor Collaborator
Mariët Hagedoorn Helen Dowling Institute

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acceptability of the couple eMBCT operationalized as intervention adherence Operationalized as percentage of couples in which the patient completed the intervention and the partner did not drop out from it. Patients' intervention completion will be recorded in the therapist log and assessed by patient self-report. If either one satisfies the completion criterion, the couple will be considered as intervention completers.
Benchmark: >= 60% of couples completed the intervention.
Throughout intervention completion, about 15-20 weeks per couple
Primary Acceptability of the couple eMBCT operationalized as satisfaction with the intervention Quantitatively operationalized as satisfaction with the dyadic approach and the intervention overall (score >= 5 indicates satisfaction, (couples only, not therapists) as assessed at T1, 2 weeks after intervention completion.
Benchmark: >= 70% of patients and 70% of partners indicating on the T1 questionnaire to be satisfied.
Throughout intervention completion, about 15-20 weeks per couple
Primary Potential efficacy on patient fatigue as assessed with the fatigue severity subscale of the Checklist Individual Strength (CIS-fatigue) from pre-intervention (T0) to 2 weeks post-intervention (T1) Fatigue is assessed with the Checklist Individual Strength, subscale fatigue severity (CIS-fatigue) on T0 (pre-intervention) and T1 (approx. 2 weeks after intervention completion). Eight items are rated on a 7-point scale, measuring fatigue in the preceding 2 weeks. The scale score ranges between 8 and 56, with a higher score indicating a higher level of fatigue.
Change in patient fatigue. The change in fatigue from T0 to T1 is tested with a matched pairs t-test and according to the intention-to-treat principle.
Benchmark: a statistically significant (p < .05) decrease in patient fatigue between T0 and T1.
Clinically relevant change in patient fatigue. Operationalized as a reduction on the CIS-fatigue from T0 to T1 of at least 6-points.
Benchmark: = 45% of patients score on T1 at least 6 points lower than on T0.
From the pre-intervention baseline assessment (Timepoint 0) to the post-intervention assessment, 2 weeks after intervention completion (Timepoint 1)
Secondary Feasibility of trial procedures operationalized as recruitment rate Benchmark:
Recruitment rate: = 3 couples included per month, averaged across both recruitment strategies.
Throughout study conduction, i.e. during the (planned) total of 18 months of data collection
Secondary Feasibility of trial procedures operationalized as T1 and T2 assessment adherence rate Benchmark:
T1 and T2 adherence rate: = 65% of patients and partners complete the T1 and = 60% of patients and partners complete the T2 questionnaire.
Throughout study conduction, i.e. during the (planned) total of 18 months of data collection
Secondary Feasibility of trial procedures operationalized as diary adherence rate Diary adherence rate: = 65% of diaries completed (11-14 diaries) by both patients and partners. Throughout study conduction, i.e. during the (planned) total of 18 months of data collection
Secondary Potential working mechanisms of couple eMBCT Diary data will be analyzed to assess the intervention's potential working mechanisms, i.e. whether expected improvements in targeted variables co-occur with the expected reduction in patient fatigue. The putative mechanism variables are: affect, sleep, catastrophizing, partner communication, partner interactions, self-efficacy, mindfulness and closeness. Multilevel growth curve analysis will be applied to model the time slopes of the potential mechanisms and weekly fatigue over the entire diary period.
A variable is interpreted as potential working mechanism in case the standardized covariance between the slope change factor for the outcome (fatigue) and that of the presumed mediator is significant (using a z-test where +/-1.96 is significant at the .05 level).
During diary period, 17-22 weeks
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT06058312 - Individual Food Preferences for the Mediterranean Diet in Cancer Patients N/A
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Completed NCT02909348 - Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab
Completed NCT03190811 - Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors Phase 1/Phase 2

External Links